We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Haleon | LSE:HLN | London | Ordinary Share | GB00BMX86B70 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.30 | -0.88% | 373.60 | 373.50 | 373.70 | 376.30 | 372.60 | 373.80 | 2,413,948 | 13:56:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Offices-holdng Companies,nec | 11.3B | 1.05B | 0.1148 | 32.67 | 34.43B |
Date | Subject | Author | Discuss |
---|---|---|---|
11/8/2022 07:56 | Absolute disaster not accepting Unliver's £50 billion bid at Christmas. IPO at only £28 billion, £10 billion of debt, GSK lost £12 billion and, terrible IPO, and share price crashes 15% within 3 weeks, value just £24 billion. Haleon just a brand holder, ripe for a take over and asset stripping, no future here! HALEON PLC LON: HLN OverviewNewsCompareF 264.00 GBX -44.85 (-14.55%)past month 11 Aug, 08:53 BST • Disclaimer | paul planet_earth | |
11/8/2022 07:37 | Thanks Spyder. Can't understand why HLN is so much harder hit. Would like to take a position but fearful of falling knife. | jojaken | |
11/8/2022 07:28 | There is much more about this over on the GSK board. I am confused about why both HLN and GSK are tanking - who has responsibility for the ongoing Zantac liability, why would it be both companies? The Execs should provide some clarity now. | spyder | |
11/8/2022 07:27 | It is neat to see the value of HLN below £25bn this morning. Exactly half of the supposed ULVR bid value. Always assuming that the bid was genuine on not some sort of Musk type confusion, scam. Cannot seem to get any professional comment on the situation here. | careful | |
11/8/2022 07:27 | If it is because of fears of a Zantac lawsuit, isn't GSK liable not Haleon? | jojaken | |
11/8/2022 07:24 | Thinks it’s the potential Zantac lawsuit that’s causing the indigestion in the share price | dr biotech | |
11/8/2022 07:08 | They rejected 50bn!? | spoole5 | |
10/8/2022 16:01 | If that is true, it is ok. It does not change the prospects of the company. | careful | |
10/8/2022 15:40 | Looks like an exit from someone as both gsk and Haleon in lockstep today, maybe Elliott is moving on | daneswooddynamo | |
10/8/2022 15:23 | No clue as to why the share price is collapsing today. £26bn. It seems to want to get to half of ULVR £50bn offer. (rejected) There must be a reason for such a big fall. | careful | |
10/8/2022 12:32 | Egos ahead of shareholders | spoole5 | |
10/8/2022 12:30 | Ridiculous not taking Unilever bid.Now if they bid if they do 30 billion. | montyhedge | |
10/8/2022 12:02 | £27bn market cap. ULVR £50bn bid looks toppy even allowing for about £10bn debt. We need time to get a clear picture here. | careful | |
09/8/2022 13:57 | Is that right Pfizer and GSK can't sell shares in this until November? | montyhedge | |
05/8/2022 20:33 | Are these the 1p shares worth 307? Just received a stock certificate | researchcentre123 | |
02/8/2022 09:57 | Cyclicals had a very strong 3 weeks with many up by 10-15%, perhaps now some give back in that due. The flip side is non cyclical stocks get more attention. | essentialinvestor | |
02/8/2022 09:45 | Is this share considered as safe haven. | csalvage | |
02/8/2022 08:53 | £28.6bn 9,234,573,831 shares in issue as at 18/7/22. | patientcapital | |
02/8/2022 08:37 | Price moving in the right direction today. The first few months are bound to be volatile. So many claimed to be selling their smaller holding in HLN and putting it back on to GSK. Creates opportunities. | careful | |
01/8/2022 14:14 | What is the market cap? | careful | |
01/8/2022 09:31 | I think it's far too early to judge HLN. I'm an income investor and have decided to hang on to my allocation from GSK for the time being to see how they work out, for divis particularly as my main interest in this or any share. | anhar | |
01/8/2022 06:59 | The share price is trading low and falling for a very good reason investors aren't convinced this business has any legs, huge debt pile, high inflation, rising cost base, revenues up but more so costs, plenty of cheaper generic products out there in the market place.. | paul planet_earth |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions